Programme overview

14.00 – 14.15	Opening remarks
14.15 – 15.30	Session 1. Diagnostic considerations — The nosology of CLL. — MBL: from the lab to the clinic. — Early diagnosis: how genomics can assist us? — Discussion and take-home messages.
15.30 – 16.15	Plenary talk 1. Immunological reflections on the origin, nature, and evolution of CLL
16.15 – 16.45	BREAK
16.45 – 18.00	Session 2. Deciding about the treatment: what are the pillars? — The tumour: biomarker-guided treatment. — The host: focus on frailty assessment. — Patient preferences. — Discussion and take-home messages.
18.00 – 18.45	Plenary talk 2. A multi-omics perspective to the origin, nature, and evolution of CLL
18.45 – 20.00	Welcome reception

09.00 – 10.15	Session 3. Targeted therapies: biological rationale and clinical implications — From bench to bedside: Targeting signalling pathways. — From bench to bedside: Targeting apoptosis. — Combined inhibition of signalling and anti-apoptotic pathways. — Discussion and take-home messages.
10.15 – 11.00	Plenary talk 3. The molecular basis of resistance to treatment
11.00 – 11.30	BREAK
11.30 – 13.00	Hands on workshops. Round 1 To be repeated 3 times – twice on Thursday and once on Friday. Each participant will have the chance to attend 3 different workshops. — Workshop 1. Genomic aberrations. — Workshop 2. Immunogenetics. — Workshop 3. MRD. — Workshop 4. Optimizing clinical outcomes.
13.00 – 14.00	LUNCH
14.00 – 15.30	Session 4. Round table: optimizing treatment outcomes
15.30 – 16.15	Plenary talk 4. Cellular therapies in CLL – present and future
16.15 – 16.45	BREAK
16.45 – 18.15	Hands on workshops. Round 2
18.15 – 19.00	Plenary talk 5. The microenvironment in CLL – lessons from mouse models

09.00 – 10.15	Session 5. Managing CLL in the era of COVID-19 — Outcomes of patients with CLL developing COVID-19. — Outcomes of vaccination against SARS-CoV-2. — Practical considerations. — Discussion and take-home messages.
10.15 – 10.45	BREAK
10.45 – 12.15	Hands on workshops. Round 3
12.15 – 13.00	Plenary talk 6. My vision of the future of CLL
13.00 – 13.15	Closing remarks
13.15 – 14.15	LUNCH